IO Biotech to Reduce Headcount by 50% Amid Restructuring

Dow Jones

2025/09/29

By Connor Hart

IO Biotech will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies.

The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance.

Shares tumbled 75% to 39 cents in premarket trading.

IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added.

The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the restructuring.

IO Biotech had 80 full-time employees at the end of 2024, according to the most recent headcount available in Securities and Exchange Commission filings.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 29, 2025 07:46 ET (11:46 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571059380"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571059380\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571059380?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571059380","market":"nz","top_or_hot":-1,"title":"IO Biotech to Reduce Headcount by 50% Amid Restructuring","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/IOBT\">IO Biotech</a> will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies. \n</p>\n<p>\n  The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance. \n</p>\n<p>\n  Shares tumbled 75% to 39 cents in premarket trading. \n</p>\n<p>\n  IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added. \n</p>\n<p>\n  The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the restructuring. \n</p>\n<p>\n  IO Biotech had 80 full-time employees at the end of 2024, according to the most recent headcount available in Securities and Exchange Commission filings. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2025 07:46 ET (11:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IO Biotech to Reduce Headcount by 50% Amid Restructuring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIO Biotech to Reduce Headcount by 50% Amid Restructuring\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-09-29 19:46</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/IOBT\">IO Biotech</a> will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies. \n</p>\n<p>\n  The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance. \n</p>\n<p>\n  Shares tumbled 75% to 39 cents in premarket trading. \n</p>\n<p>\n  IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added. \n</p>\n<p>\n  The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the restructuring. \n</p>\n<p>\n  IO Biotech had 80 full-time employees at the end of 2024, according to the most recent headcount available in Securities and Exchange Commission filings. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2025 07:46 ET (11:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2571059380","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571059380","pubTimestamp":1759146360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"IO Biotech will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies.The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance.Shares tumbled 75% to 39 cents in premarket trading.IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added.The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the res","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IOBT":"IO Biotech, Inc."},"translate_title":"IO Biotech将在重组中裁员50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOBT":1.5},"content_text":"By Connor Hart \n\n\n \n\n\nIO Biotech will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies. \n\n\n  The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance. \n\n\n  Shares tumbled 75% to 39 cents in premarket trading. \n\n\n  IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added. \n\n\n  The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the restructuring. \n\n\n  IO Biotech had 80 full-time employees at the end of 2024, according to the most recent headcount available in Securities and Exchange Commission filings. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 29, 2025 07:46 ET (11:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}